Direct central action of intramuscularly injected botulinum toxin: Is it harmful or beneficial?

Journal of Physiology

Volumn 591, Issue 4, 2013, Pages 749-749

  Kaji, Ryuji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A;

CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GRIP STRENGTH; HUMAN; LIMB MOVEMENT; MOTONEURON; NERVE CELL INHIBITION; NERVE CELL PLASTICITY; NONHUMAN; NOTE; PRIORITY JOURNAL; RENSHAW CELL; SPASTICITY; STROKE PATIENT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; MUSCLE SPASTICITY; MUSCLE, SKELETAL;

EID: 84873723207     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2012.246322     Document Type: Note

References (5)

1. Akaike N, Shin MC, Wakita M, Torii Y, Harakawa T, Ginnaga A, Kato K, Kaji R & Kozaki S (2013). Transynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol 591, 1031-1043.
2. Caleo M & Schiavo G (2009). Central effects of tetanus and botulinum neurotoxins. Toxicon 54, 593-599.
3. Filipovic B, Matak I, Bach-Rojecky L & Lackovic Z (2012). Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS One 7, e29803.
4. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M, GSK1358820 Spasticity Study Group (2010). Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 26, 1983-1992.
5. Marchand-Pauvert V, Aymard C, Giboin LS, Dominici F, Rossi A & Mazzocchio R (2013). Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A. J Physiol 591, 1017-1029